vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Verisign (VRSN). Click either name above to swap in a different company.
Verisign is the larger business by last-quarter revenue ($425.3M vs $247.1M, roughly 1.7× ANI PHARMACEUTICALS INC). Verisign runs the higher net margin — 48.5% vs 11.1%, a 37.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 7.6%). Verisign produced more free cash flow last quarter ($285.1M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Verisign, Inc. is an American company based in Reston, Virginia, that operates a diverse array of network infrastructure, including two of the Internet's thirteen root nameservers, the authoritative registry for the .com, .net, and .name generic top-level domains and the .cc country-code top-level domains, and the back-end systems for the .jobs and .edu sponsored top-level domains.
ANIP vs VRSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $425.3M |
| Net Profit | $27.5M | $206.2M |
| Gross Margin | — | 88.5% |
| Operating Margin | 14.1% | 67.0% |
| Net Margin | 11.1% | 48.5% |
| Revenue YoY | 29.6% | 7.6% |
| Net Profit YoY | 367.5% | 7.7% |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $425.3M | ||
| Q3 25 | $227.8M | $419.1M | ||
| Q2 25 | $211.4M | $409.9M | ||
| Q1 25 | $197.1M | $402.3M | ||
| Q4 24 | $190.6M | $395.4M | ||
| Q3 24 | $148.3M | $390.6M | ||
| Q2 24 | $138.0M | $387.1M | ||
| Q1 24 | $137.4M | $384.3M |
| Q4 25 | $27.5M | $206.2M | ||
| Q3 25 | $26.6M | $212.8M | ||
| Q2 25 | $8.5M | $207.4M | ||
| Q1 25 | $15.7M | $199.3M | ||
| Q4 24 | $-10.3M | $191.5M | ||
| Q3 24 | $-24.2M | $201.3M | ||
| Q2 24 | $-2.3M | $198.8M | ||
| Q1 24 | $18.2M | $194.1M |
| Q4 25 | — | 88.5% | ||
| Q3 25 | — | 88.4% | ||
| Q2 25 | — | 88.0% | ||
| Q1 25 | — | 87.7% | ||
| Q4 24 | — | 87.8% | ||
| Q3 24 | — | 88.0% | ||
| Q2 24 | — | 87.8% | ||
| Q1 24 | — | 87.2% |
| Q4 25 | 14.1% | 67.0% | ||
| Q3 25 | 15.9% | 67.8% | ||
| Q2 25 | 6.6% | 68.5% | ||
| Q1 25 | 13.3% | 67.4% | ||
| Q4 24 | -2.3% | 66.7% | ||
| Q3 24 | -13.8% | 68.9% | ||
| Q2 24 | 3.7% | 68.8% | ||
| Q1 24 | 14.8% | 67.4% |
| Q4 25 | 11.1% | 48.5% | ||
| Q3 25 | 11.7% | 50.8% | ||
| Q2 25 | 4.0% | 50.6% | ||
| Q1 25 | 8.0% | 49.5% | ||
| Q4 24 | -5.4% | 48.4% | ||
| Q3 24 | -16.3% | 51.5% | ||
| Q2 24 | -1.7% | 51.4% | ||
| Q1 24 | 13.2% | 50.5% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $580.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $-2.2B |
| Total Assets | $1.4B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $580.5M | ||
| Q3 25 | $262.6M | $617.7M | ||
| Q2 25 | $217.8M | $593.8M | ||
| Q1 25 | $149.8M | $648.5M | ||
| Q4 24 | $144.9M | $599.9M | ||
| Q3 24 | $145.0M | $644.9M | ||
| Q2 24 | $240.1M | $689.9M | ||
| Q1 24 | $228.6M | $924.7M |
| Q4 25 | $540.7M | $-2.2B | ||
| Q3 25 | $505.8M | $-2.1B | ||
| Q2 25 | $436.8M | $-2.0B | ||
| Q1 25 | $418.6M | $-2.0B | ||
| Q4 24 | $403.7M | $-2.0B | ||
| Q3 24 | $405.9M | $-1.9B | ||
| Q2 24 | $455.8M | $-1.8B | ||
| Q1 24 | $452.0M | $-1.6B |
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.4B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $1.5B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $289.6M |
| Free Cash FlowOCF − Capex | $29.1M | $285.1M |
| FCF MarginFCF / Revenue | 11.8% | 67.0% |
| Capex IntensityCapex / Revenue | 0.5% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $289.6M | ||
| Q3 25 | $44.1M | $307.7M | ||
| Q2 25 | $75.8M | $202.5M | ||
| Q1 25 | $35.0M | $291.3M | ||
| Q4 24 | $15.9M | $231.5M | ||
| Q3 24 | $12.5M | $253.4M | ||
| Q2 24 | $17.4M | $160.4M | ||
| Q1 24 | $18.3M | $257.3M |
| Q4 25 | $29.1M | $285.1M | ||
| Q3 25 | $38.0M | $303.0M | ||
| Q2 25 | $71.8M | $194.7M | ||
| Q1 25 | $32.5M | $285.5M | ||
| Q4 24 | $13.5M | $222.0M | ||
| Q3 24 | $7.7M | $247.8M | ||
| Q2 24 | $13.0M | $151.2M | ||
| Q1 24 | $13.7M | $253.5M |
| Q4 25 | 11.8% | 67.0% | ||
| Q3 25 | 16.7% | 72.3% | ||
| Q2 25 | 34.0% | 47.5% | ||
| Q1 25 | 16.5% | 71.0% | ||
| Q4 24 | 7.1% | 56.1% | ||
| Q3 24 | 5.2% | 63.4% | ||
| Q2 24 | 9.4% | 39.1% | ||
| Q1 24 | 10.0% | 66.0% |
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 1.9% | ||
| Q1 25 | 1.3% | 1.4% | ||
| Q4 24 | 1.3% | 2.4% | ||
| Q3 24 | 3.2% | 1.4% | ||
| Q2 24 | 3.2% | 2.4% | ||
| Q1 24 | 3.3% | 1.0% |
| Q4 25 | 1.10× | 1.40× | ||
| Q3 25 | 1.66× | 1.45× | ||
| Q2 25 | 8.87× | 0.98× | ||
| Q1 25 | 2.23× | 1.46× | ||
| Q4 24 | — | 1.21× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | 1.00× | 1.33× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
VRSN
Segment breakdown not available.
